Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 9.

Journal Article

Baertsch, Marc-A., Schlenzka, Jana, Christina, Habermehl, Hielscher, Thomas, Raab, Marc S., Hillengass, Jens, Mueller-Tidow, Carsten, Luntz, Steffen, Jauch, Anna, Brossart, Peter, Goerner, Martin, Klein, Stefan A., Schmidt-Hieber, Martin, Reimer, Peter, Graeven, Ullrich, Fenk, Roland, Haenel, Mathias, Martin, Hans, Lindemann, Hans-Walter, Scheid, Christoph, Nogai, Axel, Salwender, Hans Juergen, Noppeney, Richard, Weisel, Katja and Goldschmidt, Hartmut (2018). Subgroup Analyses of the Randomized GMMG Phase III Multicenter Trial Relapse Suggest Survival Benefit of Salvage Autologous Transplant Primarily in Low Risk Multiple Myeloma. Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Baertsch, Marc-Andrea, Schlenzka, Jana, Lisenko, Katharina, Krzykalla, Julia, Becker, Natalia, Weisel, Katja, Noppeney, Richard, Martin, Hans, Lindemann, Hans W., Haenel, Mathias, Nogai, Axel, Scheid, Christof, Salwender, Hans ORCID: 0000-0001-7803-0814, Fenk, Roland, Graeven, Ullrich, Reimer, Peter, Schmidt-Hieber, Martin, Goerner, Martin, Schmidt-Wolf, Ingo G. H., Klein, Stefan, Ho, Anthony D., Goldschmidt, Hartmut and Wuchter, Patrick (2017). Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE. Eur. J. Haematol., 99 (1). S. 42 - 51. HOBOKEN: WILEY. ISSN 1600-0609

Baertsch, Marc-Andrea, Schlenzka, Jana, Mai, Elias K., Merz, Maximilian, Hillengass, Jens, Raab, Marc S., Hose, Dirk, Wuchter, Patrick, Ho, Anthony D. ORCID: 0000-0002-1656-0833, Jauch, Anna, Hielscher, Thomas, Kunz, Christina, Luntz, Steffen, Klein, Stefan, Schmidt-Wolf, Ingo G. H., Goerner, Martin, Schmidt-Hieber, Martin, Reimer, Peter, Graeven, Ullrich, Fenk, Roland, Salwender, Hans ORCID: 0000-0001-7803-0814, Scheid, Christof, Nogai, Axel, Haenel, Mathias, Lindemann, Hans W., Martin, Hans, Noppeney, Richard, Weisel, Katja and Goldschmidt, Hartmut (2016). Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma. BMC Cancer, 16. LONDON: BMC. ISSN 1471-2407

Boenner, Florian, Fenk, Roland, Kochanek, Matthias and Pfister, Roman (2017). 2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity. Dtsch. Med. Wochenschr., 142 (24). S. 1826 - 1831. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1439-4413

Einsele, Hermann, Raab, Marc, Kroeger, Nicolaus, Fenk, Roland, Scheid, Christoph, Munshi, Nikhil, Petrocca, Fabio, Hege, Kristen, Novick, Steven, Raje, Noopur and Kochenderfer, James (2020). The B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T Cell Therapy Idecabtagene Vicleucel (Ide-Cel; Bb2121) in Relapsed and Refractory Multiple Myeloma (Rrmm): Outcomes from a Phase 1 Study Support the Phase 3 Karmma-3 Study Design to Compare IDE-Cel Versus Standard Triplet Regimens. Oncol. Res. Treat., 43. S. 213 - 214. BASEL: KARGER. ISSN 2296-5262

Goldschmidt, Hartmut, Baertsch, Marc-A., Schlenzka, Jana, Becker, Natalia, Christina, Habermehl, Hielscher, Thomas, Raab, Marc S., Hillengass, Jens, Mueller-Tidow, Carsten, Luntz, Steffen, Jauch, Anna, Brossart, Peter, Goerner, Martin, Klein, Stefan A., Schmidt-Hieber, Martin, Reimer, Peter, Graeven, Ullrich, Fenk, Roland, Haenel, Mathias, Martin, Hans, Lindemann, Hans-Walter, Scheid, Christoph, Nogai, Axel, Salwender, Hans Juergen, Noppeney, Richard and Weisel, Katja (2018). Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Results of the Randomized GMMG Phase III Multicenter Trial Relapse. Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Goldschmidt, Hartmut, Baertsch, Marc-Andrea, Schlenzka, Jana, Becker, Natalia, Habermehl, Christina, Hielscher, Thomas, Raab, Marc-Steffen, Hillengass, Jens, Sauer, Sandra, Mueller-Tidow, Carsten, Luntz, Steffen, Jauch, Anna, Hose, Dirk, Seckinger, Anja, Brossart, Peter, Goerner, Martin, Klein, Stefan, Schmidt-Hieber, Martin, Reimer, Peter, Graeven, Ullrich, Fenk, Roland, Haenel, Mathias, Martin, Hans, Lindemann, Hans W., Scheid, Christoph, Nogai, Axel, Salwender, Hans, Noppeney, Richard, Besemer, Britta and Weisel, Katja . Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. Leukemia. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Salwender, Hans, Bertsch, Uta, Weisel, Katja, Duerig, Jan, Kunz, Christina, Benner, Axel, Blau, Igor W., Raab, Marc Steffen, Hillengass, Jens, Hose, Dirk, Huhn, Stefanie, Hundemer, Michael, Andrulis, Mindaugas, Jauch, Anna, Seidel-Glaetzer, Andrea, Lindemann, Hans-Walter, Hensel, Manfred, Fronhoffs, Stefan, Martens, Uwe, Hansen, Timon, Wattad, Mohammed, Graeven, Ullrich, Munder, Markus, Fenk, Roland, Haenel, Mathias, Scheid, Christof and Goldschmidt, Hartmut (2019). Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. BMC Cancer, 19. LONDON: BMC. ISSN 1471-2407

Wuchter, Patrick, Bertsch, Uta, Salwender, Hans-Juergen, Munder, Markus, Haenel, Mathias, Benner, Axel, Becker, Natalia, Fenk, Roland, Duerig, Jan, Blau, Igor Wolfgang, Lisenko, Katharina, Hillengass, Jens, Raab, Marc S., Baertsch, Marc Andrea, Seidel-Glaetzer, Andrea, Ho, Anthony D., Graeven, Ullrich, Scheid, Christof, Weisel, Katja and Goldschmidt, Hartmut (2016). Evaluation of Stem Cell Mobilization in Patients with Multiple Myeloma after Lenalidomide-Based Induction Chemotherapy within the GMMG-HD6 Trial. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

This list was generated on Fri Apr 26 06:12:57 2024 CEST.